← 返回首页
美国 · 通讯社与实时数据 · Business Wire

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

来源：Business Wire · 美国 10 小时前

PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the ...

在 Business Wire 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.businesswire.com)

推荐阅读

PR Newswire

Groove Commerce Rebrands as The B2B eCommerce Agency for Manufacturers and Distributors

 Associated Press (Business)

8 innovative gifts meant to change up how we drive, cook, sleep and more

 Dow Jones Newswires

Rethinking AI in Enterprise Intelligence

 MT Newswires

Global Financial News from MT Newswires Now Live in Microsoft Copilot